Rapport Therapeutics (RAPP) said Friday that data from a proof-of-concept study of RAP-219 showed a link between a seizure biomarker and clinical seizures.
The data showed that a 30% reduction in long episode frequency was associated with a decrease of at least 50% in clinical seizures, regardless of the antiseizure medication used, according to the company.
This sets the benchmark for evaluating the potential efficacy of antiseizure treatments, including RAP-219, the company said.
Price: 20.17, Change: -0.11, Percent Change: -0.52
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。